ReNeuron Group plc Wins grant for retinal cell therapy development (3700L)
April 19 2018 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 3700L
ReNeuron Group plc
19 April 2018
19 April 2018 AIM: RENE
ReNeuron Group plc
("ReNeuron" or "the Company")
Wins grant for retinal cell therapy development
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, is pleased to announce that
it is the lead industry participant in a new GBP1.5 million grant
award from the UK's innovation agency, Innovate UK, to advance
development of its hRPC stem cell therapy candidate for
blindness-causing degenerative diseases of the retina.
The grant has been awarded under Innovate UK's Medicines and
Manufacturing Round 1: Challenge Fund and will co-fund a
collaborative programme of work to be undertaken by ReNeuron and
its partners, the Cell & Gene Therapy Catapult, Roslin Cell
Therapies and University College London. The project will allow the
generation of further cell banks of ReNeuron's hRPC cell therapy
candidate as well as the development of product release assays for
late-stage clinical development and subsequent commercialisation of
the therapy.
ReNeuron's hRPC cell therapy candidate is currently being tested
in a Phase I/II clinical trial in the US, in patients suffering
from the blindness-causing disease, retinitis pigmentosa. This new
grant follows an earlier grant awarded by Innovate UK which
supported the late pre-clinical development of the hRPC cell
therapy candidate.
Commenting on the results, Sharon Grimster, General Manager
Wales, at ReNeuron said:
"We and our collaborators are delighted to have won this latest
grant from Innovate UK to develop a suite of robust and reliable
release and characterisation assays reflecting the mechanism of
action of our hRPC cell therapy candidate. This is a challenging
but vital part of the broader commercial manufacturing strategy for
the therapy and we are pleased to be working with leading academic
and commercial manufacturing partners on this important programme
of work."
ENDS
Enquiries:
+44 (0)20 3819
ReNeuron 8400
Olav Hellebø , Chief Executive
Officer
Michael Hunt, Chief Financial
Officer
+44 (0) 20
Buchanan 7466 5000
Mark Court, Sophie Wills, Stephanie
Watson
Stifel Nicolaus Europe Limited
Jonathan Senior, Stewart Wallace,
Ben Maddison (NOMAD and Joint +44 (0) 20
Broker) 7710 7600
N+1 Singer Advisory LLP +44 (0) 20
Mark Taylor (Joint Broker) 7496 3000
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESZVLFFVZFXBBZ
(END) Dow Jones Newswires
April 19, 2018 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024